Immunome (IMNM) Share-based Compensation (2019 - 2026)

Immunome has reported Share-based Compensation for 8 years, with the latest figure at $8.0 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 39.45% year-over-year to $8.0 million; the trailing twelve-month figure through Mar 2026 stood at $27.9 million (up 44.83% YoY), and the FY2025 full-year result was $25.7 million, up 63.13% from the prior year.
• Share-based Compensation for Q1 2026 stood at $8.0 million, up from $7.9 million in the prior quarter.
• The five-year high for Share-based Compensation was $8.0 million in Q1 2026, with the low at $1.0 million in Q2 2023.
• Historically, Share-based Compensation has averaged $3.6 million across 5 years, with a median of $2.9 million in 2023.
• Annual changes were most pronounced in 2023 — Share-based Compensation dropped 22.16% — and 2024, when it jumped 351.71%.
• Immunome's Share-based Compensation stood at $1.4 million in 2022, then soared by 112.77% to $2.9 million in 2023, then soared by 89.73% to $5.5 million in 2024, then soared by 44.3% to $7.9 million in 2025, then rose by 0.76% to $8.0 million in 2026.
• The last three Share-based Compensation figures came in at $8.0 million (Q1 2026), $7.9 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.